ProNAi Therapeutics, Inc. (NASDAQ:SRRA) – Stock analysts at SunTrust Banks increased their FY2017 earnings per share (EPS) estimates for ProNAi Therapeutics in a note issued to investors on Thursday. SunTrust Banks analyst Y. Suneja now forecasts that the biotechnology company will post earnings of ($0.84) per share for the year, up from their prior forecast of ($0.92). SunTrust Banks also issued estimates for ProNAi Therapeutics’ Q4 2017 earnings at ($0.20) EPS, Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.19) EPS, FY2018 earnings at ($0.86) EPS, FY2020 earnings at ($1.00) EPS and FY2021 earnings at ($1.00) EPS.
ProNAi Therapeutics (NASDAQ:SRRA) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.03.
A number of other equities research analysts have also issued reports on SRRA. Jefferies Group LLC restated a “hold” rating on shares of ProNAi Therapeutics in a report on Thursday, July 27th. ValuEngine upgraded shares of ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research lowered shares of ProNAi Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. ProNAi Therapeutics currently has an average rating of “Hold” and an average price target of $4.00.
Shares of ProNAi Therapeutics (NASDAQ SRRA) opened at $1.92 on Monday. ProNAi Therapeutics has a 1-year low of $1.10 and a 1-year high of $2.25.
A hedge fund recently bought a new stake in ProNAi Therapeutics stock. FMR LLC acquired a new stake in ProNAi Therapeutics, Inc. (NASDAQ:SRRA) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000. FMR LLC owned 0.38% of ProNAi Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 55.65% of the company’s stock.
About ProNAi Therapeutics
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.